Study of Serum Levels of Oxidative Stress Markers in Ovarian Hyperstimulation Patients

Serum Levels of IMA, TAC, TOS, OSI and MDA in Severe OHSS Patients Underwent Long Agonist Protocol Intracytoplasmic Sperm for Determining Oxidative Stress Status

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02202278

Enrollment

Registered

2014-07-29

Start date

2014-06-30

Completion date

2014-10-31

Last updated

2014-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Hyperstimulation Syndrome

Keywords

ovarian hyperstimulation, Oxidative Stress, IMA, OHSS, ICSI, long agonist protocol, TAC, TOS, OSI, MDA

Brief summary

The aim of the study is to determine serum oxidative stress status by ischemia modified albumin (IMA), total antioxidant capacity (TAC), total oxidative capacity (TOS), oxidative stress capacity (OSI), and serum malondialdehyde (MDA) in patients with OHHS and control group. We also aim to reveal the association between serum levels of these factors and oocyte quality.

Detailed description

* Patients included in this study were assisted reproductive technique (ART) patients with moderate and severe OHSS who were hospitalized for management * Control patients are selected from patients without signs of OHSS * All patients are administered luteal long protocol for controlled ovarian stimulation. Pituitary down-regulation with SC injection of GnRH agonist (GnRH-a) (1 mg/day; Lucrin, Abbott Laboratories, North Chicago, IL) that was started on day 21 of the previous menstrual cycle. Subcutaneous administration of recombinant hFSH (Gonal-F, Laboratories Serono S.A., Aubonne, Switzerland) at dosages from 150-225 IU/day is initiated on the second or third day of menstruation. * When there are at least two or three follicles \>17 mm in diameter, recombinant human chorionic gonadotropin (0.25 µgr ; Ovitrelle IM, Serono, Istanbul, Turkey) is applied subcutaneously 34-36 hours before oocyte retrieval. * Serum samples are collected on day of HCG for study and control group patients. * Serum levels of ischemia modified albumin (IMA), malondialdehyde (MDA), total oxidative capacity (TOS), total antioxidative capacity (TAS) and oxidative stress capacity (OSI) levels. * This is a case control study * Statistical analyses will be performed using student t-test and fisher chi-square test. The correlations between the serums IMA, TAC, TOC, OSI, and MDA levels will be examined in all study groups using Spearman correlation analysis.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Inclusion criteria

• Patients in both groups are normoresponders or hyperresponders who will undergo assisted reproductive technology for male factor

Exclusion criteria

* known inherited or acquired thrombophilia * previous thromboembolism * previous, current or planned anti-thrombotic treatment * first degree relatives with known genetic thrombophilia * systemic diseases * smoking.

Design outcomes

Primary

Measure	Time frame	Description
Change the levels of oxidative stress markers	1 day	Serum will be obtained for studiying ischemia modified albumin (IMA), malondialdehyde (MDA), total oxidative capacity (TOS), total antioxidative capacity (TAS) and oxidative stress capacity (OSI) levels

Countries

Turkey (Türkiye)

Contacts

Primary Contactemine seda guvendag guven, MD

emineseda@yahoo.com905332339854

Backup Contactsuleyman guven, MD

drsuleymanguven@yahoo.com90

Outcome results